Loading clinical trials...
Loading clinical trials...
The Efficacy and Safety of Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia.
Conditions
Interventions
Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation
haploidentical hematopoietic stem cell transplantation
Locations
1
China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Start Date
June 6, 2022
Primary Completion Date
November 1, 2023
Completion Date
March 1, 2024
Last Updated
August 11, 2022
NCT03050268
NCT07216443
NCT07295951
NCT04726241
NCT05735717
NCT04065399
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions